Tags

Type your tag names separated by a space and hit enter

Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials.
SN Compr Clin Med. 2020; 2(8):1120-1131.SC

Abstract

The following systematic review and meta-analysis compile the current data regarding human controlled COVID-19 treatment trials. An electronic search of the literature compiled studies pertaining to human controlled treatment trials with COVID-19. Medications assessed included lopinavir/ritonavir, arbidol, hydroxychloroquine, tocilizumab, favipiravir, heparin, and dexamethasone. Statistical analyses were performed for common viral clearance endpoints whenever possible. Lopinavir/ritonavir showed no significant effect on viral clearance for COVID-19 cases (OR 0.95 [95% CI 0.50-1.83]). Hydroxychloroquine also showed no significant effect on COVID-19 viral clearance rates (OR 2.16 [95% CI 0.80-5.84]). Arbidol showed no 7-day (OR 1.63 [95% CI 0.76-3.50]) or 14-day viral (OR 5.37 [95% CI 0.35-83.30]) clearance difference compared to lopinavir/ritonavir. Review of literature showed no significant clinical improvement with lopinavir/ritonavir, arbidol, hydroxychloroquine, or remdesivir. Tocilizumab showed mixed results regarding survival. Favipiravir showed quicker symptom improvement compared to lopinavir/ritonavir and arbidol. Heparin and dexamethasone showed improvement with severe COVID-19 cases requiring supplemental oxygenation. Current medications do not show significant effect on COVID-19 viral clearance rates. Tocilizumab showed mixed results regarding survival. Favipiravir shows favorable results compared to other tested medications. Heparin and dexamethasone show benefit especially for severe COVID-19 cases.

Links

Authors+Show Affiliations

Department of Medicine, Banner University Medical Center South Campus, 2800 E. Ajo Way, Tucson, AZ 85713 USA.

Department of Medicine, Banner University Medical Center South Campus, 2800 E. Ajo Way, Tucson, AZ 85713 USA.

Department of Medicine, Banner University Medical Center South Campus, 2800 E. Ajo Way, Tucson, AZ 85713 USA.

Department of Medicine, Banner University Medical Center South Campus, 2800 E. Ajo Way, Tucson, AZ 85713 USA.

Department of Medicine, Banner University Medical Center South Campus, 2800 E. Ajo Way, Tucson, AZ 85713 USA.

Department of Medicine, Banner University Medical Center South Campus, 2800 E. Ajo Way, Tucson, AZ 85713 USA.

Department of Medicine, Banner University Medical Center South Campus, 2800 E. Ajo Way, Tucson, AZ 85713 USA.

Pub Type(s)

Journal Article

Review

Language

eng

PubMed ID

32838169

Citation

Siordia, Juan A., et al. "Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials." SN Comprehensive Clinical Medicine, vol. 2, no. 8, 2020, pp. 1120-1131.

Siordia JA, Bernaba M, Yoshino K, et al. Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials. SN Compr Clin Med. 2020;2(8):1120-1131.

Siordia, J. A., Bernaba, M., Yoshino, K., Ulhaque, A., Kumar, S., Bernaba, M., & Bergin, E. (2020). Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials. SN Comprehensive Clinical Medicine, 2(8), 1120-1131. https://doi.org/10.1007/s42399-020-00399-6

Siordia JA, et al. Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials. SN Compr Clin Med. 2020;2(8):1120-1131. PubMed PMID: 32838169.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials. AU - Siordia,Juan A,Jr AU - Bernaba,Michael, AU - Yoshino,Kenji, AU - Ulhaque,Abid, AU - Kumar,Sooraj, AU - Bernaba,Mario, AU - Bergin,Edward, Y1 - 2020/07/15/ PY - 2020/07/07/accepted PY - 2020/8/25/pubmed PY - 2020/8/25/medline PY - 2020/8/25/entrez KW - Arbidol KW - COVID-19 KW - Coronavirus KW - Dexamethasone KW - Favipiravir KW - Heparin KW - Hydroxychloroquine KW - Lopinavir/ritonavir KW - Remdesivir KW - SARS-CoV2 KW - Tocilizumab KW - Treatment KW - Trials SP - 1120 EP - 1131 JF - SN comprehensive clinical medicine JO - SN Compr Clin Med VL - 2 IS - 8 N2 - The following systematic review and meta-analysis compile the current data regarding human controlled COVID-19 treatment trials. An electronic search of the literature compiled studies pertaining to human controlled treatment trials with COVID-19. Medications assessed included lopinavir/ritonavir, arbidol, hydroxychloroquine, tocilizumab, favipiravir, heparin, and dexamethasone. Statistical analyses were performed for common viral clearance endpoints whenever possible. Lopinavir/ritonavir showed no significant effect on viral clearance for COVID-19 cases (OR 0.95 [95% CI 0.50-1.83]). Hydroxychloroquine also showed no significant effect on COVID-19 viral clearance rates (OR 2.16 [95% CI 0.80-5.84]). Arbidol showed no 7-day (OR 1.63 [95% CI 0.76-3.50]) or 14-day viral (OR 5.37 [95% CI 0.35-83.30]) clearance difference compared to lopinavir/ritonavir. Review of literature showed no significant clinical improvement with lopinavir/ritonavir, arbidol, hydroxychloroquine, or remdesivir. Tocilizumab showed mixed results regarding survival. Favipiravir showed quicker symptom improvement compared to lopinavir/ritonavir and arbidol. Heparin and dexamethasone showed improvement with severe COVID-19 cases requiring supplemental oxygenation. Current medications do not show significant effect on COVID-19 viral clearance rates. Tocilizumab showed mixed results regarding survival. Favipiravir shows favorable results compared to other tested medications. Heparin and dexamethasone show benefit especially for severe COVID-19 cases. SN - 2523-8973 UR - https://www.unboundmedicine.com/medline/citation/32838169/Systematic_and_Statistical_Review_of_Coronavirus_Disease_19_Treatment_Trials_ DB - PRIME DP - Unbound Medicine ER -